参考文献/References:
[1] Dobesh PP,Beavers CJ,Herring HR,et al.Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention:2012 update[J].Pharmacotherapy,2012,32(12):e348-e386.
[2] Shuldiner AR,O'Connell JR,Bliden KP,et al.Association of cytochromeP450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
[3] Rai M,Seip RL,Gupta A,et al.CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance[J].Conn Med,2012,76(5):267-272.
[4] Al Shamiri MQ,Abdel Gader AM,Bayoumy NM.Evaluation of resistance to anti-platelet therapy in patients with coronary heart disease in a developing country[J].Clin Lab,2014,60(9):1449-1455.
[5] Liu T,Yin T,Li Y,et al.CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention[J].Coron Artery Dis,2014,25(5):412-420.
[6] Park KJ,Chung HS,Kim SR,et al.Clinical,pharmacokinetic,and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome[J].Korean J Lab Med,2011,31(2):91-94.
[7] Wright RS,Anderson JL,Adams CD,et al.2011 ACCF/AHA focused update ofthe guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline):a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the American College of Emergency Physicians,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons[J].J Am Coll Cardiol,2011,57(19):e215-e367.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
Cardiology branch of Chinese Medical Association,Editorial Committee of Chinese Journal of cardiovascular disease.Guidelines for diagnosis and treatment of non-ST segment elevation acute coronary artery syndrome[J].Chin JCardiol,2012,40(5):353-367.
[9] 吴干斌,周建华,刘科兰.河南汉族冠心病患者CYP2 C19基因多态性分布[J].郑州大学学报(医学版),2014,49(4):568-571.
Wu GB,Zhou JH,Liu KL.Distribution of CYP2 C19 genetic polymorphism in patients of Han nation ality with coronary artery disease from Henan Province[J].Journal of Zhengzhou University(Medical Science),2014,49(4):568-571.
[10] 热依汗·依明,帕丽达·阿布来提,古丽扎尔·买买提明. 维吾尔族、汉族冠心病人群CYP2C19基因多态性分析[J].心血管康复医学杂志,2014,23(2):127-130.
Reyihan YM,Palida ABLT,Gulizhaer MT.Genetic polymorphism analysis of CYP2C19 in Uighur and Han nationality patients with coronary heart disease[J].Chin J Cardiovasc Rehabil Med,2014,23(2):127-130.
[11] Sorich MJ,Rowland A,McKinnon RA,et al.CYP2 C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel:a meta-analysis[J].Circ Cardiovasc Genet,2014,7(6):895-902.
[12] Jeong YH,Tantry US,Kim IS,et al.Effect of CYP2 C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin[J].Circ Cardiovasc Interv,2011,4(6):585-594.
相似文献/References:
[1]洪骏,王锋,印中鹏,等.冠心病患者血浆纤维蛋白原与脂蛋白相关磷脂酶A2水平[J].现代检验医学杂志,2015,30(05):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
HONG Jun,WANG Feng,YIN Zhong-peng,et al.Levels of Plasma Lipoprotein Associated Phospholipase A2
and Fibrinogen in Patients with Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2015,30(03):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
[2]赵佳a,姚创利a,左林,等.冠心病患者血清同型半胱氨酸对血脂和锰超氧化物歧化酶的影响[J].现代检验医学杂志,2015,30(05):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
ZHAO Jiaa,YAO Chuang-lia,ZUO Lin,et al.Effects of Homocysteine on Blood Lipid and Manganese Superoxide
Dismutase in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(03):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
[3]李 垚,杨 平.早发冠心病触珠蛋白水平及其在免疫调节中的作用研究[J].现代检验医学杂志,2015,30(01):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
LI Yao,YANG Ping.Role of Haptoglobin in the Immunomodulatory
in Patients with Premature Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(03):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
[4]张 蕾,陈 捷,陈玉婷.冠心病并发恶性肿瘤患者Ghrelin/obestatin比值变化及意义[J].现代检验医学杂志,2016,31(04):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
ZHANG Lei,CHEN Jie,CHEN Yu-ting.Change and Significance of Ghrelin/Obestatin in Patients
with Coronary Heart Disease Complicated with Malignant Tumor[J].Journal of Modern Laboratory Medicine,2016,31(03):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
[5]赵 佳,左 林,姚创利,等.冠心病患者血清同型半胱氨酸水平与氧化应激的关系研究[J].现代检验医学杂志,2016,31(05):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
ZHAO Jia,ZUO Lin,YAO Chuang-li,et al.Study on the Relationship between Serum Homocysteine Levels
and Oxidative Stress in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(03):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
[6]姚创利,黎 阳,鲁旭娟,等.超氧化物歧化酶及其同工酶和超敏C-反应蛋白与冠心病的关系[J].现代检验医学杂志,2016,31(05):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
YAO Chuang-li,LI Yang,LU Xu-juan,et al.Relationship of Superoxide Dismutase Isoenzyme and High
Sensitive C-Reactive Protein with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(03):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
[7]黄生金,郑利平,陆俊佳,等.广西地区壮族和汉族冠心病患者胱抑素C水平及其基因多态性的比较研究[J].现代检验医学杂志,2017,32(03):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
HUANG Sheng-jin,ZHENG Li-ping,LU Jun-jia,et al.Comparative Study of Cystatin C and Its Gene Polymorphism of Pati
ents
with Coronary Heart Disease between Zhuang and Han in Guangxi Region[J].Journal of Modern Laboratory Medicine,2017,32(03):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
[8]王跃帮,吴 娟,崔 倩,等.IL-6基因启动子区域-572C>G和-174G>C多态性与江苏宿迁汉族人群冠心病的相关性[J].现代检验医学杂志,2018,33(03):31.[doi:10.3969/j.issn.1671-7414.2018.03.010]
WANG Yue-bang,WU Juan,CUI Qian,et al.Association between Interleukin-6-572C>G
and -174G>C Gene Polymorphism in the Promoter Region
and Coronary Heart Disease of Han Population in Suqian of Jiangsu[J].Journal of Modern Laboratory Medicine,2018,33(03):31.[doi:10.3969/j.issn.1671-7414.2018.03.010]
[9]刘亚东,冯莉莉,王海晶,等.冠心病患者血清Lp-PLA2与HCY检测及其与冠状动脉病变程度的相关性分析[J].现代检验医学杂志,2018,33(06):83.[doi:10.3969/j.issn.1671-7414.2018.06.022]
LIU Ya-dong,FENG Li-li,WANG Hai-jing,et al.Detection of Serum Lp-PLA2 and HCY in Patients with Coronary Heart Disease and Its Correlation with the Degree of Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2018,33(03):83.[doi:10.3969/j.issn.1671-7414.2018.06.022]
[10]李苗苗,王玉红,刘 静.中国沈阳地区汉族冠心病患者CYP2C19基因多态性分布特征[J].现代检验医学杂志,2019,34(02):5.[doi:10.3969/j.issn.1671-7414.2019.02.002]
LI Miao-miao,WANG Yu-hong,LIU jing.Distribution Characteristics of CYP2C19 Gene Polymorphismin Han Patients with Coronary Heart Disease in Shenyang,China[J].Journal of Modern Laboratory Medicine,2019,34(03):5.[doi:10.3969/j.issn.1671-7414.2019.02.002]